Rating Change
Chardan Capital analysts downgraded EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) from Buy to Neutral on August 18, 2026.
downgradeNASDAQ:EYPT
EyePoint Pharmaceuticals, Inc. (EYPT) Downgraded to Neutral by Chardan Capital
Chardan Capital analysts downgraded EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) from Buy to Neutral on August 18, 2026.
At publication ·
What changed
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) · downgrade
- Firm
- Chardan Capital
- Rating
- Buy to Neutral
- Price at event
- $5.23
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Chardan Capital downgraded EyePoint Pharmaceuticals from Buy to Neutral on August 18, 2026, though the stock still has 6 Buy ratings among the 10 most recent analyst ratings.
Market Context
EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $5.23 with a market capitalization of $1.1B. The stock has declined 55.1% over the past 52 weeks.
Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Chardan Capital's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | RBC Capital | Sector Perform | N/A |
| Aug 18, 2026 | Chardan Capital | Neutral | N/A |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Aug 17, 2026 | Jefferies | Buy | N/A |
| Aug 17, 2026 | JP Morgan | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page
Frequently Asked Questions
What does the Neutral rating mean for EYPT?
A rating of Neutral from Chardan Capital reflects the analyst's outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EYPT forecast page.